Despite substantial efforts dedicated to the development of new, nonaddictive analgesics,
success in treating pain has been limited. Clinically available analgesic agents generally …

There is a critical need for effective new pharmacotherapies for pain. The paucity of new
drugs successfully reaching the clinic calls for a reassessment of current analgesic drug …

Biomedical science has greatly improved our understanding of pain in recent decades, but
few novel molecular entities that address fundamentally new pain mechanisms have …

Chronic pain is a disabling disease with limited treatment options. While animal models
have revealed important aspects of pain neurobiology, therapeutic translation of this …

Chronic pain affects one in five of the general population and is the third most important
cause of disability-adjusted life-years globally. Unfortunately, treatment remains inadequate …

Introduction: Neuropathic pain is a costly and disabling condition, which affects up to 8% of
the population. Available therapies often provide incomplete pain relief and treatment …

Preclinical pain research has applied state-of-the-art methods over the past 40 years to
describe, characterize, and image molecules, cells, and circuits in rodents to understand the …

Acute and chronic pain complaints, although common, are generally poorly served by
existing therapies. This unmet clinical need reflects a failure to develop novel classes of …

Chronic pain is a constantly recurring and persistent illness, presenting a formidable
healthcare challenge for patients and physicians alike. Current first‐line analgesics offer …

In the majority of patients, existing therapies for neuropathic pain are far from effective.
Furthermore, all current treatments are symptomatic rather than disease-modifying or …